GSK Vaccine Sales Hit By COVID-19 But Initial Signs Of Recovery
Group Sales Down 3% As UK Vaccine Supply Deal Is Struck
Executive Summary
GlaxoSmithKline sees initial signs of recovery from the coronavirus pandemic in terms of vaccination rates and highlights its growing research progress against COVID, RSV and meningitis, although a UK expert warns against over-optimism.
You may also be interested in...
GSK Sees Light At End Of Shingrix Tunnel As COVID-19 Eases
A CDC recommendation slowed non-pandemic vaccinations, but Shingrix shots will likely increase as more eligible consumers are fully vaccinated against SARS-CoV-2.
Coronavirus Update: BioNTech And Fosun Launch Vaccine Trial In China
The study is designed to support the regulatory approval process in China and confirm that the safety and immunogenicity profile observed in German and US trials is comparable to that of Chinese participants, according to BioNTech.
Sanofi/GSK Working With The US To Increase COVID-19 Vaccine Capacity
The $2.1bn investment under the US’ Operation Warp Speed will fund development, scale-up of US manufacturing and the first 100 million doses.